V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens

Viruses from 15 of 35 maraviroc-treated participants with virologic failure and CCR5-tropic (R5) virus in the MOTIVATE studies at Week 24 had reduced maraviroc susceptibility. On-treatment amino acid changes were observed in the viral envelope glycoprotein 120 third variable (V3)–loop stems and tips...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, ME, Simpson, P, Mori, J, Jubb, B, Sullivan, J, McFadyen, L, van der Ryst, E, Craig, C, Robertson, DL, Westby, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369958/
https://www.ncbi.nlm.nih.gov/pubmed/34343443
http://dx.doi.org/10.1177/20402066211030380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369958/
https://www.ncbi.nlm.nih.gov/pubmed/34343443
http://dx.doi.org/10.1177/20402066211030380

Ejemplares similares